Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 8Hypothyroidism 6Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Alveolar Soft Part 1Recurrence 1Postoperative Complications 1Polycystic Ovary Syndrome 1Neoplasms 1Infertility, Female 1Goiter 1Fatigue 1Depression 1Brain Neoplasms 1Anxiety Disorders 1Advanced Differentiated Thyroid Gland Carcinoma 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Thyroxine × Clear all
NCT06087068 2023-10-17

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
140 enrolled
Head & Neck

Recurrence, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡